

**SUPPLEMENTARY DATA**

**Table 1 of the supplementary data.** All the covariates and their estimates in the multivariable model for noncardiovascular mortality risk

	HR (95%CI)	P
Age	1.02 (1.00-1.02)	< .001
Male sex	1.40 (1.17-1.67)	< .001
First HF admission	1.08 (0.89-1.29)	.437
NYHA class III-IV	1.24 (1.01-1.59)	.037
Charlson index	1.05 (1.00-1.11)	.036
Heart rate at admission	0.75 (0.33-1.72)	.508
SBP at admission	1.00 (0.99-1.00)	.106
Hemoglobin, g/dL	0.96 (0.92-1.00)	.086
NT-proBNP, pg/mL	1.05 (0.95-1.15)	.343
CA125, UI/mL	1.05 (0.97-1.13)	.213
Glomerular filtration rate, mL/min	1.00 (0.99-1.00)	.637
BUN, mg/dL	0.99 (0.99-1.01)	.739
Loop diuretic dose at discharge	1.00 (0.98-1.02)	.758
RAAS inhibitors at discharge	1.00 (0.85-1.19)	.955
Betablockers at discharge	0.70 (0.59-0.82)	<.001
MRA at discharge	0.93 (0.77-1.13)	.471

BUN, blood urea nitrogen; CA, carbohydrate antigen; CI, confidence interval; HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.

**Table 2 of the supplementary data.** All the covariates and their estimates in the multivariable model for risk of recurrent noncardiovascular admissions

	HR (95%CI)	P
Age, y	1.01 (1.00-1.01)	<.001
Male sex	1.36 (1.23-1.51)	<.001
First HF admission	0.97 (0.87-1.08)	.581
NYHA class III-IV	1.19 (1.05-1.34)	.007
Charlson index	1.13 (1.01-1.6)	<.001
Heart rate at admission	0.65 (0.51 - 1.02)	.062
SBP at admission	1.00 (0.99-1.01)	.535
Hemoglobin, g/dL	0.93 (0.90-0.95)	<.001
NT-proBNP, pg/mL	1.05 (0.99-1.00)	.082
CA125, UI/mL	1.07 (1.03-1.12)	<.001
Glomerular filtration rate, mL/min	1.00 (0.98-1.00)	.707
BUN, mg/dL	0.99 (0.99-1.01)	.659
Loop diuretic dose at discharge	0.99 (0.98-1.00)	.550
RAAS inhibitors at discharge	1.00 (0.92-1.10)	.837
Betablockers at discharge	0.74 (0.74-0.90)	<.001
MRA at discharge	0.83 (0.74-0.92)	<.001

BUN, blood urea nitrogen; CA, carbohydrate antigen; CI, confidence interval; HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; RAAS, renin-angiotensin-aldosterone system; SBP, systolic blood pressure.